Peptide inhibitors of protein kinase C
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorDaria Mochly-Rosen
Life of this patent
Estimating the term…
Abstract
PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.
Claims14
A peptide comprising at least six to twelve amino acid residues that are at least 50% identical to amino acids residues of a variable 5 (V5) domain of a delta protein kinase C (PKC) isozyme (SEQ ID NO:26), wherein said peptide inhibits delta PKC isozyme activity, provided that said peptide is not SEQ ID NO:31.
A pharmaceutical formulation comprising a pharmaceutically acceptable excipient and a peptide comprising at least six to twelve amino acid residues that are at least 50% identical to amino acids residues of a variable 5 (V5) domain of a delta protein kinase C (PKC) isozyme (SEQ ID NO:26), wherein said peptide inhibits delta PKC isozyme activity, provided that said peptide is not SEQ ID NO:31.
Dependencies are inferred from the claim text.